Cycle on Jul 11, 2026

I will start by listing the topic's open threads to see if there are specific user-prioritized research questions or active watches we need to address or monitor. I'm using `list_threads` first.

I will search for recent news on the active FDA advisory committee meetings and regulatory deadlines scheduled for late July 2026, specifically focusing on the Capricor deramiocel advisory committee (scheduled for July 29, 2026) and Replimune's RP1 advisory committee meeting. I'll search with `recent=true` and `sort="recent"`.

I see that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to meet on July 29, 2026, to discuss Capricor's BLA for deramiocel, and on July 30, 2026, to discuss Replimune's BLA for RP1 (ipilimumab-like or oncolytic immunotherapy). Let's fetch the official FDA meeting announcement or a relevant news article to get more details on both. I will search for "Replimune" "RP1" BLA "July 30, 2026" or similar to see what's happening.

Let's fetch the FDA's official meeting announcement page for the July 30, 2026 CTGTAC meeting to verify the exact details of the Replimune RP1 review. This is a very reliable source. Let's do `web_fetch` for `https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-30-2026-meeting-announcement-07302026`.

I will search for the Capricor deramiocel meeting details as well, to confirm the date and parameters. Let's do a search.

Excellent! We have confirmed the details of the two upcoming FDA advisory committee meetings: 1. Capricor Therapeutics' BLA for **deramiocel** (for DMD cardiomyopathy) is confirmed to be reviewed by the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) on **July 29, 2026**. 2. Replimune's BLA for **RP1 (vusolimogene oderparepvec)** in combination with nivolumab for advanced melanoma is confirmed to be reviewed by the CTGTAC on **July 30, 2026**. Let's do a search on other potential new developments. For example, let's search for "H5N1" "Australia" to see if there is any update on the ongoing H5N1 watch there. I'll search with `recent=true` and `sort="recent"`.

This is a major update! Australia has detected H5 bird flu in a **local** seabird (a greater crested tern) for the first time, marking a significant step beyond the initial detections in migratory birds. Let's fetch one of these pages to get the exact quotes, details, and context. I will fetch `https://www.scimex.org/newsfeed/expert-reaction-h5n1-bird-flu-detected-in-a-local-bird-for-the-first-time`.

This is a highly consequential development for our ongoing H5N1 watch in Australia. Let's record this event. The thread ID is `019f2f50-7f4d-7361-8f05-cdf170c2d727`. The title of the watch is "Australia H5N1 transmission to poultry or local wildlife". This watch is ongoing, so we will set `resolves: false`. Let's call `record_event` to update it.

Excellent! Now let's see if there are other updates or new research on diseases, biology, or space. Let's search for "Amgen" "Tavneos" to see if there is any update on the extended deadline of July 29, 2026. I'll search for recent news. Let's do a `web_search`.

Ah, let's look at this article from BioSpace: "Amgen continues to defend Tavneos as global regulatory pressure mounts" published very recently (July 10, 2026). Let's fetch it to see the latest updates on the Tavneos situation! This is extremely relevant to our prior finding `amgen-tavneos-eu-revocation-us-fda-extension`. Let's do `web_fetch` for `https://www.biospace.com/business/amgen-continues-to-defend-tavneos-as-global-regulatory-pressure-mounts`.

This is perfect! We have a solid update on the Tavneos story. Let's update the existing note `amgen-tavneos-eu-revocation-us-fda-extension` using its stable slug. But first, let's see if there are other updates or new research topics we can cover. Let's do a quick search on "disease outbreaks", "drug approvals", or "breakthroughs in biology/energy/space" with `recent=true` and `sort="recent"` to find other fresh, highly consequential news from the last week. Let's search for "FDA approval" or "EMA approval".

This is an incredible list of fresh stories! Let's drill into a few of them: 1. **Roche ending development of both tominersen and RG6496 in Huntington's disease** on July 10, 2026. This is a very significant setback in neurology. Let's do a search on this! 2. **FDA decision on gedatolisib (first targeted therapy for PIK3CA wild-type breast cancer)** expected by July 17, 2026. 3. **FDA approval of subcutaneous isatuximab-irfc (Sarclisa Escena) via on-body injector** on July 9, 2026. 4. **First cannabis-based medication for chronic pain to launch in Europe (Germany and Austria)** next month. Let's do a search on Roche's Huntington's disease program termination to read the full story. I'll search with `recent=true`.

This is a monumental piece of biotechnology/neurology news. I'll fetch `https://en.hdbuzz.net/roche-ends-two-huntingtons-disease-drug-programmes-after-disappointing-results/` to read the full scientific detail. This is a dedicated Huntington's disease research news platform (HDBuzz) which will give us deep, accurate scientific context. Let's do `web_fetch`.

This is an incredibly rich, robust, and important finding. I will write a new note for this. The slug should track the durable subject, which is Huntington's disease clinical development or gene-silencing therapies, e.g. `huntingtons-disease-gene-silencing-roche-tominersen-setback`. Let's also check the status of uniQure's AMT-130 BLA submission watch `019ed7c8-8ce2-7ba0-9576-f823526d0677`. The description states "Monitor uniQure's formal submission of the BLA for AMT-130 in Huntington's disease, targeted for Q3 2026." Since it's currently July 11, 2026, let's do a quick search on uniQure's AMT-130 to see if there is any update in recent days. I'll search with `recent=true`.

Let's fetch the Tech Times article to read the full details of how Roche's termination of tominersen and RG6496 contrasts with the uniQure AMT-130 program. This is an excellent, highly analytical piece of journalism tying these together. I'll fetch `https://www.techtimes.com/articles/320124/20260710/roche-ends-both-huntingtons-disease-drug-programs-after-biomarkers-beat-patients.htm`.

This is an incredibly rich, well-written, and detailed article that perfectly explains the science, the mechanisms of both tominersen and RG6496, the biomarker-clinical dissociation (the "biomarker paradox"), and contrasts it with uniQure's AMT-130 gene therapy program, Skyhawk's SKY-0515, and Novartis's votoplam. I will write a detailed, high-quality finding note. The slug will be `huntingtons-disease-gene-silencing-roche-tominersen-setback`. Let's check if there are other topics to cover first. Is there any news on the other watches? Let's look at: - "Gedatolisib breast cancer FDA approval expected by July 17, 2026." Let's do a search on gedatolisib to see if there is any new update or background. - "FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena) for all multiple myeloma indications" on July 9, 2026. This is a brand new FDA approval. Let's do a quick search on this. - "First cannabis-based medication for chronic pain to launch in Europe (Germany and Austria) next month." Let's search for this. Let's do a quick search on these three items to see which one is the most impactful to write a note on. I'll search with `recent=true` and `sort="recent"`.

This is another incredibly important and fresh FDA approval! Sanofi's Sarclisa Escena becomes the first FDA-approved anticancer treatment administered via an on-body injector, raising the anti-CD38 competition in multiple myeloma against J&J's Darzalex Faspro. Let's write two findings this cycle: 1. Revise/update the Tavneos regulatory crisis note: `amgen-tavneos-eu-revocation-us-fda-extension`. 2. Write a new note on the major Huntington's disease gene-silencing setback: `huntingtons-disease-gene-silencing-roche-tominersen-setback`. Wait, let's also write a note on Sanofi's subcutaneous Sarclisa Escena approval, which is a major drug approval and a breakthrough in drug delivery (the first anticancer treatment delivered via a hands-free on-body injector). Let's use the slug `sanofi-sarclisa-escena-subcutaneous-on-body-injector-myeloma`. Let's first write the update for Tavneos. I'll call `write_note` for `amgen-tavneos-eu-revocation-us-fda-extension`.

Now, let's write the note on the major Huntington's disease gene-silencing setback. This is a brand new finding. I will write a note with the slug `huntingtons-disease-gene-silencing-roche-tominersen-setback`. Let's call `write_note`.

Now, let's write a note on the FDA approval of Sanofi's subcutaneous Sarclisa Escena, which represents the first-ever anticancer treatment delivered via a hands-free on-body injector, upping the anti-CD38 competition in multiple myeloma. Let's call `write_note` with slug `sanofi-sarclisa-escena-subcutaneous-on-body-injector-myeloma`.

Now let's check our active watches and see if we can resolve any of them. - We have a watch: `019f1fe0-09fc-7028-9aca-1d1dd5636118` "Amgen Tavneos FDA hearing submission extended deadline" (Fires when Amgen submits its independent re-adjudication results to the FDA by the extended deadline of July 29, 2026). - This has *not* fired yet because the deadline is July 29, 2026, and Amgen is still preparing to submit it. - We have a watch: `019ed7c8-8ce2-7ba0-9576-f823526d0677` "uniQure BLA submission for AMT-130 in Huntington's disease" (Fires when uniQure formally submits the BLA in Q3 2026). - This has *not* fired yet, as the application is planned for Q3 2026 (we are in early July). - We have a watch: `019f2f50-7f4d-7361-8f05-cdf170c2d727` "Australia H5N1 transmission to poultry or local wildlife". - This has *not* resolved since it is an ongoing watch, but we successfully recorded an event on it! - We have a watch: `019f061f-f34a-7079-a276-d216329928b2` "FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy" (Fires when the FDA Cellular, Tissue, and Gene Therapies Advisory Committee votes on or discusses the approval of deramiocel, scheduled for July 29, 2026). - This has *not* fired yet because the date is July 29, 2026. - We have a watch: `019f0620-007b-7dab-87b4-0363a2496ea1` "FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma" (Fires when the FDA advisory committee meets to discuss or vote on Replimune's RP1, scheduled for July 30, 2026). - This has *not* fired yet because the date is July 30, 2026. Wait, let's register a new watch for the upcoming FDA decision on gedatolisib in PIK3CA wild-type breast cancer, which is expected by July 17, 2026. This is a highly dated catalyst! Let's call `record_watch` to register this.

Now let's call `finish_cycle` to complete this research cycle, as we have written all our notes and recorded the events/watches. I'll call `finish_cycle`.

I have successfully completed the research cycle for this topic. Here is a summary of the findings and actions taken: ### 1. Key Findings & Updates Posted * **Amgen's Tavneos Regulatory Crisis Updated (`amgen-tavneos-eu-revocation-us-fda-extension`):** Updated the standing note to reflect Amgen's ongoing preparation of the Duke Clinical Research Institute (DCRI) re-adjudication data for its final FDA hearing submission due by **July 29, 2026**. Highlighted the financial stakes, including the $2.4 billion carrying value of intangible assets tied to the drug. * **Roche's Huntington's Disease Programs Discontinued (`huntingtons-disease-gene-silencing-roche-tominersen-setback`):** Documented the major double-termination of Roche's **tominersen** (Phase 2 GENERATION HD2) and **RG6496** (Phase 1 POINT-HD) programs. Detailed the "biomarker paradox" (where tominersen successfully lowered mutant huntingtin and reduced NfL but failed to show any functional or clinical benefit on the cUHDRS and TFC scales over 16 months). Contrasted this intrathecal ASO failure with the surgical gene therapy approach of uniQure's **AMT-130**, which is on track for a **Q3 2026 BLA submission** for accelerated approval. * **FDA Approves Sanofi's Subcutaneous Sarclisa Escena (`sanofi-sarclisa-escena-subcutaneous-on-body-injector-myeloma`):** Recorded the landmark FDA approval of Sanofi's subcutaneous formulation of **isatuximab-irfc** for multiple myeloma, administered via a hands-free, on-body injector—representing the first-ever anticancer treatment delivered via this method. This directly intensifies competition against J&J's Darzalex Faspro. ### 2. Active Watches & Events Logged * **H5N1 Avian Influenza in Australia (`019f2f50-7f4d-7361-8f05-cdf170c2d727`):** Recorded a critical progress event. Laboratory testing by the CSIRO has confirmed the **first H5N1 infection in a local, resident Australian seabird** (a greater crested tern in South Australia). This marks a transition from migratory ocean vagrants to resident local wildlife, upping the risk of rapid local transmission ahead of the spring/summer breeding season. * **New Watch Registered (`019f535e-c7d5-7317-939c-855999ccce9d`):** Registered a one-shot dated catalyst watch for the upcoming **FDA decision on gedatolisib** (the first targeted therapy for PIK3CA wild-type breast cancer), expected by **July 17, 2026**.